Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) [Gastrointestinal Cancer]

Conclusion
ColDx is associated with RFI in the C9581 subsample in the presence of other prognostic factors, including MMR deficiency. ColDx could be incorporated with the traditional clinical markers of risk to refine patient prognosis.

Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Niedzwiecki, Frankel, Venook, Ye, Friedman, Goldberg, Mayer, Colacchio, Mulligan, Davison, OBrien, Kerr, Johnston, Kennedy, Harkin, Schilsky, Bertagnolli, Warren, Innocenti Tags: Translational Oncology, Gastrointestinal, Gene Expression and Profiling Gastrointestinal Cancer Source Type: research